Evidence map›Paper›PMID 40931802›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2026

Severe course of tick-borne encephalitis (TBE) in a patient with relapsing multiple sclerosis (MS) treated with ocrelizumab.

Jonathan A Gernert, Matthias Klein, Florian Schöberl, Katharina J Müller, Moritz L Schmidbauer, Robert Forbrig, Sigrun Roeber, Jochen Herms, Nicole Terpolilli, Milena Milakovic Obradovic and 5 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jonathan A GernertInstitute of Clinical Neuroimmunology, LMU University Hospital, LMU Munich, Munich, Germany; Department of Neurology with Friedrich Baur Institute, LMU University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0002-6655-5557
Matthias KleinDepartment of Neurology with Friedrich Baur Institute, LMU University Hospital, LMU Munich, Munich, Germany.
Florian SchöberlDepartment of Neurology with Friedrich Baur Institute, LMU University Hospital, LMU Munich, Munich, Germany.
Katharina J MüllerDepartment of Neurology with Friedrich Baur Institute, LMU University Hospital, LMU Munich, Munich, Germany.
Moritz L SchmidbauerDepartment of Neurology with Friedrich Baur Institute, LMU University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0001-9553-9911
Robert ForbrigInstitute of Neuroradiology, LMU University Hospital, LMU Munich, Munich, Germany.
Sigrun RoeberCenter for Neuropathology and Prion Research, Faculty of Medicine, LMU Munich, Munich, Germany.
Jochen HermsCenter for Neuropathology and Prion Research, Faculty of Medicine, LMU Munich, Munich, Germany.
Nicole TerpolilliDepartment of Neurosurgery, LMU University Hospital, LMU Munich, Munich, Germany.
Milena Milakovic ObradovicMax Von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Ludwig Maximilian University, Munich, Germany; German Center for Infection Research (DZIF), Partner site Munich, Munich, Germany.
Alexander GrafLaboratory for Functional Genome Analysis, Gene Center, LMU Munich, Munich, Germany.ORCID 0000-0003-4435-6861
Christopher DächertMax Von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Ludwig Maximilian University, Munich, Germany.
Oliver T KepplerMax Von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Ludwig Maximilian University, Munich, Germany; German Center for Infection Research (DZIF), Partner site Munich, Munich, Germany.
Maximilian MünchhoffMax Von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Ludwig Maximilian University, Munich, Germany; German Center for Infection Research (DZIF), Partner site Munich, Munich, Germany.
Konstantinos DimitriadisDepartment of Neurology with Friedrich Baur Institute, LMU University Hospital, LMU Munich, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Description of a patient with multiple sclerosis (MS) who underwent immunotherapy with ocrelizumab and suffered a severe course of tick-borne encephalitis (TBE): A 33-year-old man presented with acute cerebellitis with tonsillar herniation. The initial suspected diagnosis of TBE was confirmed after a significant diagnostic delay, likely caused by negative serological testing due to B-cell depletion from ocrelizumab treatment for underlying MS. TBE diagnosis was made using polymerase chain reaction (PCR) and oligo-hybrid capture metagenomic next-generation sequencing (mNGS) of cerebral spinal fluid and brain biopsy samples which yielded a near-full length TBE Virus (TBEV) genome.

Indexed as

Antibodies, Monoclonal, HumanizedEncephalitis, Tick-BorneImmunologic FactorsMultiple Sclerosis, Relapsing-RemittingAdultEncephalitis Viruses, Tick-BorneHumansMaleAntibodies, Monoclonal, HumanizedImmunologic FactorsocrelizumabMultiple sclerosisocrelizumabtick-borne encephalitisviral infection

Identifiers

PMID40931802
PMCPMC13168594

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.